Systemic lupus erythematosus risk factors for coronary artery calcifications

Rheumatology

Volumn 51, Issue 1, 2012, Pages 110-119

  Romero Díaz, Juanita ^a   Vargas Vóracková, Florencia ^b   Kimura Hayama, Erick ^c   Cortázar Benítez, Luis F ^a   Gijón Mitre, Rubén ^a   Criales, Sergio ^a   Cabiedes Contreras, Javier ^a   Iñiguez Rodríguez, María del Rocío ^a   Lara García, Eunice Alejandra ^a   Núñez Alvarez, Carlos ^a   Llorente, Luis ^a   Aguilar Salinas, Carlos ^b   Sánchez Guerrero, Jorge ^a  

^a Department of Immunology and Rheumatology ^*  (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Atherosclerosis; Coronary artery calcifications; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; APOLIPOPROTEIN B; CYCLOSPORIN; IMMUNOGLOBULIN G; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREDNISONE; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALARIA; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; POSTMENOPAUSE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGE FACTORS; CALCINOSIS; CORONARY ARTERY DISEASE; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LIPIDS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84855166628     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker307     Document Type: Article

References (38)

1. Systemic lupus erythematosus. In: Silman AJ, Hochberg MC (eds). Epidemiology of the rheumatic diseases. New York: Oxford University Press, 1993:163-91.
2. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-5.
3. Manzi S, Meilahn EN, Rairie JE et al. Age specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997;145:408-15.
4. Roman MJ, Shanker BA, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406.
5. Asanuma Y, Oeser A, Shintani AK et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2407-15.
6. Esdaile JM, Panaritis C, Abrahamowicz M. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7.
7. Manger K, Kusus M, Forster C et al. Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis 2003;62:846-50.
8. Asanuma Y, Chung CP, Oeser A et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006;33:539-45.
9. Rho YH, Chung CP, Oeser A et al. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheumatol 2008;35:1789-94.
10. Ahmad Y, Shelmerdine J, Bodill H et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and lupus phenotype. Rheumatology 2007;46:983-8.
11. Kiani AN, Magder L, Petri M. Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. J Rheumatol 2008;35:1300-6.
12. Hochberg MC; for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
13. Urowitz MB, Gladman D, Ibañez D et al. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res 2010;62: 881-7.
14. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
15. Gladman DD, Ginzler E, Goldsmith C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
16. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97: 1837-47.
17. McCollough CH, Ulzheimer S, Salliburton SS, Shanneik K, White RD, Lakender WA. Coronary artery calcium: a multi-institutional, multimanufacturer international standard for quantification at cardiac CT. Radiology 2007;43: 527-38.
18. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827-32.
19. Ibañez D, Gladman DD, Urowitz MB. Adjusted mean systemic lupus erythematosus activity index-2K is a predictor of outcome in SLE. J Rheumatol 2005;32: 824-7.
20. Hahn BH. Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med 2003;349:2379-80.
21. Jara LJ, Medina G, Vera-Lastra O, Shoenfeld Y. Atherosclerosis and antiphospholipid syndrome. Clin Rev Allergy Immunol 2003;25:79-88.
22. Hochman J, Urowitz MB, Ibañez D, Gladman DD. Hormone replacement therapy in women with systemic lupus erythematosus and risk of cardiovascular disease. Lupus 2009;18:313-7.
23. Kiani AN, Vogel-Claussen J, Magder L, Petri M. Noncalcified coronary plaque in systemic lupus erythematosus. J Rheumatol 2010;37:579-84.
24. Peters MJL, Symmons DPM, Dijkmans BAC et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69:325-31.
25. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141:764-70.
26. McMahon M, Grossman J, Skaggs B et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 2009;60:2428-37.
27. Wallace DJ, Linker-Israeli M, Metzger AL, Stecher VJ. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 1993;2(Suppl. 1):S13-S15.
28. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991;324:150-4.
29. Fessler BJ, Alarcon GS, McGwin G Jr. et al. Systemic lupus erythematosus in three ethnic groups. XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005;52:1473-80.
30. Ruiz-Irastorza G, Egurbide MV, Pijoan JI et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006;15:577-83.
31. Shinjo SK, Bonfá E, Wojdyla D et al. Antimalarial treatment may have a time-dependent effect on lupus survival. Arthritis Rheum 2010;62:855-62.
32. Ansel BJ, Navab M, Hama S et al. Inflammatory/ anti-inflammatory properties of high density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108:2751-6.
33. McMahon M, Grossman J, FitzGerald J et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54:2541-9.
34. O'Neill SG, Giles I, Lambrianides A et al. Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2010;62:845-54.
35. Wang G, Pirangeli SS, Papalardo E, Ansari GAS, Khan MF. Markers of oxidative and nitrosative stress in systemic lupus erythematosus. Correlation with disease activity. Arthritis Rheum 2010;62:2064-72.
36. Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 2007;28:69-75.
37. Budoff MJ, McClelland RL, Nasir K et al. Cardiovascular events with absent or minimal coronary calcification: the multi-ethnic study of atherosclerosis (MESA). Am Heart J 2009;158:554-61.
38. Bild DE, Detrano R, Peterson D et al. Ethnic differences in coronary calcification: the multi-ethnic study of atherosclerosis (MESA). Circulation 2005;111: 1313-20.